ScholarIQanswers from OpenAlex & ORCID
Philippe Merle
ResearcherPublications, citations & collaboration network
Philippe Merle is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Philippe Merle have?
ScholarIQindexed works
Philippe Merle has 419 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Philippe Merle have?
ScholarIQcitation count
Philippe Merle has 31,507 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Philippe Merle?
ScholarIQh-index
Philippe Merle has an h-index of 58 in OpenAlex.
What is the i10-index of Philippe Merle?
ScholarIQi10-index
Philippe Merle has an i10-index of 156 in OpenAlex.
What is the ORCID of Philippe Merle?
ScholarIQorcid
The ORCID for Philippe Merle is on the source record.
What is the OpenAlex record for Philippe Merle?
ScholarIQopenalex
The OpenAlex for Philippe Merle is on the source record.
What are the most-cited papers on Philippe Merle?
ScholarIQmost cited works
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Eric Assénat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Kenta Motomura, Izumi Ohno, Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerken, Christophe Borg, Jean‐Baptiste Hiriart, Takuji Okusaka, Manabu Morimoto, Yanzhi Hsu, Paolo Abada, Masatoshi Kudo
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
Valérie Vilgrain, Héléna Pereira, Eric Assenat, Boris Guiu, Alina Diana Ilonca, Georges-Philippe Pageaux, Annie Sibert, Mohamed Bouattour, Rachida Lebtahi, Wassim Allaham, Hélène Barraud, Valérie Laurent, E. Mathias, Jean-Pierre Bronowicki, J.P. Tasu, R. Perdrisot, Christine Silvain, René Gerolami, O. Mundler, Jean‐François Seitz, Vincent Vidal, Christophe Aubé, Frédéric Oberti, Olivier Couturier, Isabelle Brenot-Rossi, Jean‐Luc Raoul, Anthony Sarran, Charlotte Costentin, Emmanuel Itti, Alain Luciani, René Adam, M. Lewin, Didier Samuel, Maxime Ronot, Aurélia Dinut, Laurent Castéra, Gilles Châtellier, Eric Assenat, Elisabeth Delhom - Christol, Boris Guiu, Alina Diana Ilonca, J. Lonjon, Georges-Philippe Pageaux, Mohamed Abdel‐Rehim, Wassim Allaham, Mohamed Bouattour, Laurent Castéra, Arnaud Dieudonné, Rachida Lebtahi, Maxime Ronot, Annie Sibert, Valérie Vilgrain, Hélène Barraud, Christophe Bazin, Jean-Pierre Bronowicki, Valérie Laurent, E. Mathias, Carine Chagneau-Derrode, R. Perdrisot, Christine Silvain, J.P. Tasu, Patrick Borentain, René Gerolami, O. Mundler, Jean‐François Seitz, Vincent Vidal, Christophe Aubé, Antoine Bouvier, Olivier Couturier, Frédéric Oberti, Laurent Vervueren, Isabelle Brenot-Rossi, Jean‐Luc Raoul, Anthony Sarran, Julia Chalaye, Charlotte Costentin, Emmanuel Itti, Hicham Kobeiter, Alain Luciani, René Adam, M. Lewin, Didier Samuel, Julien Edeline, Étienne Garin, Yan Rolland, Isabelle Archambeaud, Thomas Eugène, Éric Frampas, Christophe Cassinotto, Martine Guyot, Jean‐Baptiste Hiriart, Bruno Lapuyade, Julien Vergniol, Philippe Bachellier, Julien Détour, Bernard Duclos, Michel Greget, François Habersetzer, Alessio Impériale, Philippe Merle
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Josep M. Llovet, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin, Masafumi Ikeda, Ruocai Xu, Julien Edeline, Baek‐Yeol Ryoo, Zhenggang Ren, Gianluca Masi, Mariusz Kwiatkowski, Ho Yeong Lim, Jee Hyun Kim, В. В. Бредер, Hiromitsu Kumada, Ann‐Lii Cheng, Peter R. Galle, Shuichi Kaneko, Anran Wang, Kalgi Mody, Corina E. Dutcus, Leonid Dubrovsky, Abby B. Siegel, Richard S. Finn, Simone I. Strasser, Alexander Thompson, Aflah Roohullah, William Sievert, Vladimir Andelkovic, Jennifer J. Knox, Janine M. Davies, Jamil Asselah, Mayur Brahmania, Habeeb Majeed, Luis J. Villanueva-Rivera, Patricio Yañez Weber, Marcelo Garrido, Gonzalo Pizarro, Nicolás Yáñez, Ruocai Xu, Shuangyan Ou, Zhenggang Ren, Hongming Pan, Zhiqiang Meng, Kangsheng Gu, Xi Chen, Tao Zhang, Chunyi Hao, Peiguo Cao, Yabing Guo, Shukui Qin, Juxiang Xiao, Weijia Fang, Xin Wang, Yuxian Bai, Xiaoming Chen, Dong Yan, Hong Zhao, Jieer Ying, Carlos Bonilla, Olga Urrego, Ángela R. Zambrano, Mauricio Lema, Juan Carlos Restrepo, Andrés F. Cardona, Sandra Franco Millan, Madiedo Oscar, Víctor Ramos, Philippe Merle, Samuel Lesourd, Julien Edeline, Jean–Pierre Bronowicki, Marc Bourlière, Stéphane Cattan, Mohamed Bouattour, Laurent Mineur, Hélène Regnault, Barbara Dauvois, Kornelius Schulze, Gunnar Folprecht, Andreas Geier, Oliver Waidmann, Fabian Finkelmeier, Marino Venerito, Marie‐Luise Berres, Thomas Berg, Christian M. Lange, Hartmut Schmidt, Dirk Waldschmidt, Michael Bitzer, Ray McDermott, Austin G. Duffy, Gianluca Masi, Vittorina Zagonel, Giuseppe Tonini, Fabio Piscaglia, Stefania Gori, Mimma Rizzo, Elisa Biscaldi
Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma
Lorenza Rimassa, Romano Danesi, Tiziana Pressiani, Philippe Merle